Mirati Therapeutics Receives “Market Outperform” Rating from JMP Securities (MRTX)
Mirati Therapeutics (NASDAQ:MRTX)‘s stock had its “market outperform” rating restated by equities research analysts at JMP Securities in a research note issued to investors on Monday. They currently have a $28.00 target price on the stock, up from their previous target price of $25.00. JMP Securities’ target price would indicate a potential upside of 37.66% from the stock’s previous close.
Shares of Mirati Therapeutics (NASDAQ:MRTX) traded down 0.69% during mid-day trading on Monday, hitting $20.20. 16,926 shares of the company’s stock traded hands. Mirati Therapeutics has a 52 week low of $7.00 and a 52 week high of $25.97. The stock’s 50-day moving average is $18.91 and its 200-day moving average is $19.34. The company’s market cap is $272.2 million.
Other equities research analysts have also recently issued reports about the stock. Analysts at Zacks upgraded shares of Mirati Therapeutics from an “underperform” rating to a “neutral” rating in a research note on Thursday, April 10th. They now have a $19.40 price target on the stock. Analysts at Brean Capital raised their price target on shares of Mirati Therapeutics from $20.00 to $27.00 in a research note on Tuesday, March 18th. They now have a “buy” rating on the stock. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $27.10.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.